Skip to main content

Webinar with winners of the EACR & Novosanis research grant: Part 1

We are excited to host an upcoming webinar with winners of the EACR & Novosanis research grant, which will highlight cancer biomarker detection in urine. The webinar will have two presentations, by speakers Dr. Anne-Cécile Duc and Antonija Hanžek, from CHROME at Université de Nîmes France, and Stephanie Jordaens from Novosanis.

Don't miss out! Register here today.

Disclaimer

Novosanis is a wholly owned subsidiary of OraSure Technologies, Inc. (NASDAQ: OSUR), and an innovative developer and producer of medical devices improving the quality of diagnostic tests for infectious diseases and oncology. The Colli-Pee® family, the heart of the company, allows volumetric and standardized collection of first-void urine. The platform consists of variants capturing a range of urine volumes for different application purposes. Urine collection through the Colli-Pee® device is easy, comfortable, and more accurate than a regular urine cup. First-void urine has shown to improve detection of infectious diseases, including sexually transmitted infections as well as for some cancers applications. The Colli-Pee® device enables immediate mixing of the first-void urine sample with a preservative, improving stability of the urine specimen. Novosanis markets its products worldwide and has a global customer base.